ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.